Letrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women[J]. Journal of Evidence-Based Medicine, 2003, 3(3): 163-166. DOI: 10.3969/j.issn.1671-5144.2003.03.009
|
Citation:
|
Letrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women[J]. Journal of Evidence-Based Medicine, 2003, 3(3): 163-166. DOI: 10.3969/j.issn.1671-5144.2003.03.009
|
Letrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women[J]. Journal of Evidence-Based Medicine, 2003, 3(3): 163-166. DOI: 10.3969/j.issn.1671-5144.2003.03.009
|
Citation:
|
Letrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women[J]. Journal of Evidence-Based Medicine, 2003, 3(3): 163-166. DOI: 10.3969/j.issn.1671-5144.2003.03.009
|
DownLoad: